13 Best Biotech Penny Stocks to Buy According to Hedge Funds
Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Logos Capital Arsani William | 12,500,000 | $31,375,000 | +15% | 3.67% |
2. | Suvretta Capital Management Aaron Cowen | 12,315,004 | $30,910,660 | -11% | 1.05% |
3. | Siren L.L.C. Raymond Debbane | 8,857,179 | $22,231,519 | 0.98% | |
4. | SilverArc Capital Devesh Gandhi | 7,543,901 | $18,935,192 | +9% | 4.14% |
5. | Vivo Capital Albert Cha And Frank Kung | 6,756,756 | $16,959,458 | 1.89% |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$2.27 | 80,000 | Director | 573,974 | 2024-05-21 | Filing | |
$1.85 | 10,000 | Director | 20,000 | 2023-12-06 | Filing | |
$1.72 | 278,150 | Large Shareholder, Officer, Director | 12,899,360 | 2023-12-06 | Filing | |
$1.69 | 721,850 | Large Shareholder, Officer, Director | 12,899,360 | 2023-12-05 | Filing | |
$1.66 | 30,000 | Director | 493,974 | 2023-12-04 | Filing |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$18.77 | 200,000 | Director | 10,305,553 | 2021-07-26 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 209,443 | $286,927 | 0% | |
2. | 87,251 | $119,534 | 0% | |
3. | 28,139 | $38,551 | 0% | |
4. | 11,510 | $15,769 | 0% | |
5. | 245 | $336 | 0% |